The enlargement of the hormone immune deprivation concept to the blocking of TGFα-autocrine loop: EGFR signaling inhibition

Cancer Immunology, Immunotherapy

Volumn 55, Issue 6, 2006, Pages 628-638

  Mulet, Aillette ^a   Garrido, Greta ^a   Álvarez, Anabel ^b   Menéndez, Tamara ^b   Böhmer, Frank D ^c   Pérez, Rolando ^a   Fernández, Luis Enrique ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^c JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Active specific immunotherapy; Cancer vaccine; Growth factor immunodeprivation; hTGF

Indexed keywords

BACTERIAL PROTEIN; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; IODINE 125; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P64K; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; AUTOCRINE EFFECT; AUTOPHOSPHORYLATION; CARBOXY TERMINAL SEQUENCE; CARCINOMA CELL; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; EMBRYO; ENZYME ACTIVATION; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOBLOTTING; IMMUNOGENICITY; IMMUNOTHERAPY; ISOTOPE LABELING; MOLECULAR RECOGNITION; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIBODIES, BLOCKING; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNODOMINANT EPITOPES; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 33644589205     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0030-9     Document Type: Article

References (43)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
2. Lee DC (1996) TGFα: a member of the EGF receptor ligand family. Growth Factors Cytokines Health Dis 1:277-318
3. Baselga J, Mendelson J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550-6565
4. Salomon DS, Kim N, Saeki T, Cardiello F (1990) Transforming growth factor-α: an oncodevelopmental growth factor. Cancer Cells 2:389-397
5. Kiss A, Szepesi A, Lotz G, Nagy P, Schaff Z (1998) Expression of transforming growth factor-α in hepatoblastoma. Cancer 83:690-697
6. D'Errico A, Barozzi C, Fiorentino M, Carella R, Ferruzi L, Mattioli S, Grigioni WF (2000) Role and new perspectives of transforming growth factor-α (TGF-α) in adenocarcinoma of the gastro-oesophageal junction. Br J Cancer 82:865-870
7. Iahara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S (1993) Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer 21:2902-2909
8. Hiesiger E, Hayes R, Pierz D, Budzilovich G (1993) Prognostic relevance of epidermal growth factor receptor and c-neu/erbb2 expression in glioblastoma (GBMs). Neurooncol 16:93-104
9. Rubin-Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SG, Tweady DJ (1998) Levels of TGFα and EGFR proteins in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832
10. Schreiber AB, Winkler ME, Derynck R (1986) Transforming growth factor α: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253
11. Normanno N, Bianco C, De Luca A, Salomon DS (2001) The role of EGF-related peptides in tumor growth. Front Biosci 6(May 1):d685-d707
12. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, Dandrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Meldelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone or in combination with cisplatin. J Clin Oncol 18:99-115
13. Crombet T, Torres O, Neninger E, Catalá M, Rodríguez N, Ramos M, Fernández E, Iznaga N, Pérez R (2001) Phase I clinical evaluation of neutralizing monoclonal antibody against epidermal growth factor receptor. Cancer Radiother Radiopharm 16(1):93-102
14. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG (2000) Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6(12):4885-4892
15. González G, Sánchez B, Suárez E, Beausoleil I, Pérez O, Lastre M, Lage A (1996) Induction of immune recognition of self epidermal growth factor (EGF): effect on EGF biodistribution and tumor growth. Vaccine Res 6:91-100
16. González G, Pardo OL, Sánchez B, García JL, Beausoleil I, Marinello P, González Y, Domarco A, Guillén G, Pérez R, Lage A (1997) Induction of immune recognition of self epidermal growth factor (EGF) II: characterization of the antibody response and the use of a fusion protein. Vaccine Res 6:91-100
17. González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, Marinello P, Guillén G, Lage A (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a clinical trial. Ann Oncol 9:1-5
18. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R, Lage A (2003) Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14:461-466
19. Guillen G, Alvarez A, Silva R, Morera V, Gonzalez S, Musacchio A, Besada V, Coizeau E, Caballero E, Nazabal C, Carmenate T, Gonzalez LJ, Estrada R, Tambara Y, Padron G, Herrera L (1998) Expression in Escherichia coli of the IpdA gene, protein sequence analysis and immunological characterization of the P64k protein from Neisseria meningitidis. Biotechnol Appl Biochem 27(Pt 3):189-196
20. Lowry DH, Rosebrough NJ, Farr AL, Jandall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 191:495-498
21. Estévez F, Carr A, Solorzano L, Valiente O, Mesa C, Barroso O, Sierra GV, Fernández LE (2000) Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP). Vaccine 18:190-197
22. Korc M, Finman JE (1989) Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha. J Biol Chem 264(25):14990-14999
23. Mesa C, de León J, Rigley K, Fernández LE (2004) Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 22(23-24):3045-3052
24. Soderdahl G, Betsholtz C, Johansson A, Nilsson K, Bergh J (1988) Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. Int J Cancer 41(4):636-641
25. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem Mar 275(12):8806-8811
26. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8(3):289-293
27. Suarez Pestana E, Greiser U, Sanchez B, Fernandez LE, Lage A, Perez R, Böhmer FD (1996) Synergistic growth inhibition of human lung adenocarcinoma cells by monoclonal antibodies against epidermal growth factor receptor and ganglioside GM3. Involvement of receptor-directed protein-tyrosine phosphatases. Br J Cancer 775:213-220
28. Suarez Pestana E, Greiser U, Sanchez B, Fernandez LE, Lage A, Perez R, Bohmer FD (1997) Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s). Br J Cancer 75(2):213-220
29. Tozawa K, Broadhurst RW, Raine AR, Fuller C, Alvarez A, Guillen G, Padron G, Perham RN (2001) Solution structure of the lipoyl domain of the chimeric dihydrolipoyl dehydrogenase P64K from Neisseria meningitidis. Eur J Biochem 268(18):4908-4917
30. Mann GB, Fowler KJ, Gabriel A, Nice EC, Williams RL, Dunn AR (1993) Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation. Cell 73:249-261
31. Luetteke NC, Qiu TH, Peiffer RL, Oliver P, Smithies O, Lee DC (1993) TGFα deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73:263-278
32. Normanno N, Bianco C, De Luca A, Salomon DS (2001) The role of EGF-related peptides in tumor growth. Front Biosci 6(May 1):d685-d707
33. Derynck R (1992) The physiology of transforming growth factor alpha. Adv Cancer Res 58:27-52
34. Baselga J, Mendelsohn J, Kim YM, Pandiella A (1996) Autocrine regulation of membrane transforming growth factor-alpha cleavage. J Biol Chem 271(6):3279-3284
35. Yang H, Jiang D, Li W, Liang J, Gentry LE, Brattain MG (2000) Defective cleavage of membrane bound TGF alpha leads to enhanced activation of the EGF receptor in malignant cells. Oncogene 19(15):1901-1914
36. Forsthubert T, Yip HC, Lehmann PV (1996) Induction of TH1 and TH2 immunity in neonatal mice. Science (Wash. DC) 271:1728-1730
37. Chu RS, Targoni OS, Krieg AM, Lechmann PV, Harding CV (1997) CpG Oligodeoxynucleotides acts as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186(10):1623-1631
38. Miconnet I, Coste I, Beermann F, Haeuw J-F, Cerottini J-C, Bonnefoy J-Y, Romero P, Renno T (2001) Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol 166:4612-4619
39. Blankenstein T, Qin Z (2003) The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15(2):148-154
40. Dirnhofer S, Wick G, Kris M, Read FX, Berger P (1994) The suitability of human chorionis gonadotropin (hcG)-based birth-control vaccines. Immunol Today 15:468-474
41. Watson SA, Michaeli D, Grimes S, Morris TM, Crosbee D, Wilkinson M, Robinson G, Robertson JF, Steele RJ, Hardcastle JD (1995) Anti-gastrine antibodies raised by gastroimmune inhibit growth of the human colorectal tumorAP5. Int J Cancer 61:233-240
42. Small EJ, Reese DM (2000) An update on prostate cancer research. Curr Opin Oncol 12:265-272
43. Goldberg MR, Heimbrook DC, Russo P, Sasrody MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED, Oliff AI, Pastan IH (1995) Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1:57-61